H.C. Wainwright raised the firm’s price target on MoonLake Immunotherapeutics to $75 from $37 and keeps a Buy rating on the shares. The analyst considers the company’s Phase 2 MIRA results to be the best data in hidradenitis suppurativa. The firm believes sonelokimab has a best-in-class profile and increased its probability of approval to 70%.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MLTX: